INtramyocardial application of STEM cells in combination with transmyocardial laser revascularisation in coronary artery bypass graft patients
ISRCTN | ISRCTN49998633 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN49998633 |
EudraCT/CTIS number | 2005-004051-35 |
Secondary identifying numbers | Instem_HHU_2005 |
- Submission date
- 08/05/2007
- Registration date
- 15/06/2007
- Last edited
- 08/07/2014
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Circulatory System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Not provided at time of registration
Contact information
Prof H.M. Klein
Scientific
Scientific
Department of Thoracic and Cardiovascular Surgery
Moorenstrasse 5
Duesseldorf
40225
Germany
Study information
Study design | Phase II, open, prospective, single-arm, four centre (Düsseldorf, Lübeck, Hannover und Heidelberg) clinical trial |
---|---|
Primary study design | Interventional |
Secondary study design | Multi-centre |
Study setting(s) | Hospital |
Study type | Treatment |
Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
Scientific title | |
Study acronym | INSTEM-Trial |
Study objectives | Conditions studied: Patients with poor distal vessels, total arterial occlusion, or unacceptable procedural risks due to concomitant medical conditions. Up to 15% of the patients with this end-stage coronary artery disease suffer from disabling anginal symptoms regardless of maximal pharmacotherapy and conventional revascularisations. A prospective study to assess safety and efficacy of stem cell application with regard to regional myocardial improvement in patients with Coronary Artery Bypass Graft (CABG) and Transmyocardial Laser Revascularisation (TMLR). Please note as of 24/01/2012, the anticipated start date has ben modified from 26/05/2007 to 04/05/2007. The anticipated end date was modified from 01/01/2010 to 04/01/2012. |
Ethics approval(s) | Approval received from the local ethics committee (Ethikommission der medizinischen Fakultät der Heinrich-Heine-Universität) on the 5th April 2006 (ref: MC-LKP-85). |
Health condition(s) or problem(s) studied | Coronary artery bypass graft |
Intervention | The aim of the intraoperative stem cell transplantation is to repopulate diseased myocardium with cells that could restore contractility. Results of experimental studies have shown that bone marrow derived stem cells can be used to regenerate cardiomyocytes and induce angiogenesis after myocardial infarction, resulting in improvement of myocardial function. The bone marrow aspiration and the operative procedure will be performed under one general anesthesia. The number of channels of TMLR must be at least 10 holes per territory and will be documented. The stem cells must be injected within the surrounding of these laser channels. |
Intervention type | Other |
Primary outcome measure | Safety: occurrence of Major Adverse Cardiac Event (MACE) assessed at three months after surgical study treatment. MACE will be assessed by the investigator for relationship to the interventions under the investigation in this trial. |
Secondary outcome measures | Secondary endpoints (assessed at 3, 6 and 12 months follow-up): 1. MACE assessed at 6 and 12 months follow-up 2. Cardiac Adverse Events (AEs) defined in the Common Toxicity Criteria (CTC) (assessed form onset of surgery up to 12 months follow-up) 3. Severity of angina and extent of treatment in comparison to baseline (Canadian Cardiovascular Society [CCS] classification) (assessed at 3, 6 and 12 months follow-up) 4. Quality of Life in comparison to baseline (increase of exercise tolerance in Seattle Angina Questionnaire) (assessed at 3, 6 and 12 months follow-up) 5. Baseline Regional cardiac function by cardiac MRI is assessed and in comparison to cardiac MRI at six months follow-up (in case of an contraindication against cardiac MRI the cardiac function is assessed by cardiac CT) |
Overall study start date | 04/05/2007 |
Completion date | 04/01/2012 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Adult |
Lower age limit | 18 Years |
Sex | Both |
Target number of participants | 40 (Recruitment completed, last patient visit in December 2011) |
Key inclusion criteria | 1. 18 years (male or female gender) 2. Presence of at least two vessel coronary artery disease with at least one vessel that is not amenable to CABG, according to the angiogram, this vessel must serve an area of viable myocardium 3. Area of interest defined as part of free left ventricular wall with reduced contractility as shown either in ventriculographia during angiography and/or preoperative echo 4. Demonstration of reduced perfusion in the area of interest by cardiac Magnetic Resonance Imaging (MRI) or Computed Tomography (CT) 5. Global ejection fraction greater than 15% and less than 35% 6. Signed informed consent |
Key exclusion criteria | 1. Any condition that in the belief of the treating physician prevents successful stem cell collection or application (e.g. systemic infection, puncture for stem cell collection impossible) 2. Any condition that may adversely affect bone marrow (such as malignancy or prior irradiation to the pelvic bone) 3. Mitral valve insufficiency greater than II 4. History of ventricular arrhythmia, not controlled by medication and/or Automatic Implantable Cardioverter Defibrillator (AICD) required 5. Need of additional heart surgery (i.e. valve replacement) 6. Emergency or salvage operation defined as within 48 hours of diagnosis 7. Evidence of left ventricular thrombus 8. Previous heart surgery within the last six months (excluding implantation of pacemaker) 9. History of symptomatic carotid disease (e.g. any Transient Ischaemic Attack [TIA], Prolonged Ischaemic Neurological Deficit [PRIND], stroke) within the last three months prior to study intervention 10. Increased Creatine Kinase (CK) (greater than three times normal) in patients with unstable angina 11. End Stage Renal Disease (ESRD) defined as serum creatinine level greater than 3.5 mg/dL, or dialysis (renal replacement therapy) 12. Concurrent active chemotherapy for cancer 13. Life expectancy less than two years 14. Platelet count less than 100000/µl 15. Pregnancy 16. Participation in other clinical trials in the last 30 days 17. Active hepatitis-infection 18. Human Immunodeficiency Virus (HIV)-infection 19. Anaemia 20. Haemorrhagic diathesis in medical history 21. Sensitivity and incompatibility against used drugs or excipients 22. Disseminated intravascular coagulation in medical history 23. Clinically active infection at the time of operation 24. Patient not able to attend follow-up as specified in the protocol 25. No informed consent |
Date of first enrolment | 04/05/2007 |
Date of final enrolment | 04/01/2012 |
Locations
Countries of recruitment
- Germany
Study participating centre
Department of Thoracic and Cardiovascular Surgery
Duesseldorf
40225
Germany
40225
Germany
Sponsor information
Heinrich-Heine-University (Germany)
University/education
University/education
c/o Professor H. M. Klein
Department of Thoracic and Cardiovascular Surgery
Moorenstrasse 5
Duesseldorf
40225
Germany
Website | http://www.uni-duesseldorf.de/ |
---|---|
https://ror.org/024z2rq82 |
Funders
Funder type
University/education
Heinrich-Heine-University (Germany)
No information available
PLC Medical Systems (USA)
No information available
Miltenyi Biotec (Germany) - stem cell kit supply
No information available
Results and Publications
Intention to publish date | |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Not provided at time of registration |
Publication and dissemination plan | Not provided at time of registration |
IPD sharing plan |
Study outputs
Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
---|---|---|---|---|---|
Results article | results | 07/07/2014 | Yes | No |